Moderna, Inc. MRNA
249.86 USD +21.42 (+9.38%)
Nov 4, 2026, 12:23 PM EST
230.21 Day range 253.72
22.36 52-week range 249.42
- YTD
- +747.27%
- 1 year
- +952.04%
Analyst view
Consensus: hold
Hold
Price target (mean) 138.37 -44.6% downside
Now 249.86
- Target (low)
- 45.00
- Target (mean)
- 138.37
- Target (high)
- 251.00
Ratings (0m) 23 4 buy · 15 hold · 4 sell
- Strong buy1
- Buy3
- Hold15
- Sell2
- Strong sell2
Recommendation trend
- This month 23
- 1 month ago 23
- 2 months ago 23
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.25 | -3.28 – -0.79682 | -0.51 | -146.0% | 890.22M | -12.4% | 16 |
| Next quarter | -1.86 | -2.23 – -1.50 | -2.11 | +11.8% | 675.41M | -0.4% | 13 |
| Current year | -8.49 | -10.57 – -7.95 | -7.26 | -17.0% | 2.10B | +8.1% | 21 |
| Next year | -4.90 | -7.11 – -2.73 | -8.49 | +42.3% | 2.44B | +16.3% | 19 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | William Blair | Downgrade | Outperform | Market Perform |
| Oct 26, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Oct 21, 2026 | TD Cowen | Maintained | Hold | Hold |
| Oct 15, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Oct 7, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Sep 30, 2026 | Citigroup | Downgrade | Neutral | Sell |
| Sep 3, 2026 | Rothschild & Co | Downgrade | Neutral | Sell |
| Aug 28, 2026 | Argus Research | Upgrade | Hold | Buy |
| Aug 25, 2026 | Wolfe Research | Upgrade | Underperform | Peer Perform |
| Aug 24, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Aug 21, 2026 | JP Morgan | Maintained | Underweight | Underweight |
| Aug 20, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Aug 20, 2026 | UBS | Maintained | Neutral | Neutral |
| Aug 20, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Aug 19, 2026 | William Blair | Upgrade | Market Perform | Outperform |
| Aug 3, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Jul 21, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Jul 8, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Jul 7, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Jul 7, 2026 | B of A Securities | Maintained | Underperform | Underperform |
| Jun 26, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Jun 8, 2026 | B of A Securities | Maintained | Underperform | Underperform |
| May 4, 2026 | UBS | Maintained | Neutral | Neutral |
| May 4, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| May 4, 2026 | Evercore ISI Group | Maintained | In-Line | In-Line |
| May 4, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Apr 2, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Feb 23, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Feb 17, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Feb 17, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |